European CHMP recommends approval of trastuzumab deruxtecan (Enhertu) for treatment of metastatic HER2-positive breast cancer

Trastuzumab deruxtecan is a monoclonal antibody-drug conjugate that binds to the HER2, disrupting HER2 signalling and also mediating antibody-dependent cell-mediated cytotoxicity. In addition, deruxtecan also causes DNA damage and apoptotic cell death.

European Medicines Agency